KNSA
Kiniksa Pharmaceuticals International, plc
KNSA
Kiniksa Pharmaceuticals International, plc
KNSA
Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International NASDAQ: KNSA said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-on
Kiniksa Pharmaceuticals International (NASDAQ: KNSA - Get Free Report) is projected to post its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect Kiniksa Pharmaceuticals I